Exhibit 99.1
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 –
– Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 –
– MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 –
– Entered into exclusive license agreement with Catalent for MM-120 Zydis® orally disintegrating tablet (ODT) formulation for advancement into pivotal clinical trials –
– Cash and cash equivalents of $116.9 million at June 30, 2023 –
– Company to host conference call today at 4:30 PM ET –
NEW YORK, August 3, 2023 -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2023.
“We’re coming up on a critical period for MindMed as we are close to wrapping up enrollment in our Phase 2b study of MM-120 for the treatment of generalized anxiety disorder” said Robert Barrow, Chief Executive Officer and Director of MindMed. “Our ability to enroll a study of this size in such an efficient manner stands out in the field and speaks to the remarkable quality of our R&D team. We are also excited to have licensed Catalent’s Zydis ODT technology for use with MM-120 which we believe significantly bolsters the differentiation and protectability of our MM-120 product candidate while potentially offering enhanced bioavailability and more rapid absorption, which may lead to a shorter treatment session. We could not be more excited about the progress we have made to date and the numerous upcoming milestones in the months ahead.”
Business Update
Recent Highlights and Anticipated Upcoming Milestones:
Phase 2b study evaluating MM-120 for generalized anxiety disorder (GAD) remains on track for topline readout in Q4 2023.
Phase 2a study evaluating MM-120 for attention deficit hyperactivity disorder (ADHD) continues to advance toward a topline readout in Q4 2023 / Q1 2024.
Advancing development of MM-402 (also referred to as R(-)-MDMA) for autism spectrum disorder (ASD) into first clinical trial in Q4 2023.
Collaborations and Partnerships
The Company continues to support its ongoing collaboration with the Liechti Lab at UHB in Switzerland. MindMed has exclusive worldwide rights to data, compounds and patent rights associated with UHB’s
research on lysergide and other psychedelic compounds, including data from preclinical studies and investigator-initiated clinical trials.
Second Quarter 2023 Financial Results
Cash and Cash Equivalents Balance. As of June 30, 2023, MindMed had cash and cash equivalents totaling $116.9 million compared to $142.1 million as of December 31, 2022. The Company believes its available cash and cash equivalents will be sufficient to fund its operating requirements into the first half of 2025.
Net Cash Used in Operating Activities. The net cash used in operating activities was $27.2 million for the six months ended June 30, 2023, compared to $28.0 million in the six months ended June 30, 2022.
Research and Development (R&D). R&D expenses were $14.8 million for the quarter ended June 30, 2023, compared to $9.3 million for the quarter ended June 30, 2022, an increase of $5.5 million. The increase was primarily due to increases of $4.4 million in expenses related to clinical research for the MM-120 GAD study, $0.8 million in preclinical activities, $0.6 million in internal personnel costs as a result of increasing R&D capacity, and $0.2 million in connection with various external R&D collaborations, partially offset by a decrease of $0.5 million in expenses related to our MM-110 program, and a decrease of $0.1 million related to our MM-402 program.
General and Administrative (G&A). G&A expenses were $14.4 million for the quarter ended June 30, 2023, compared to $7.6 million for the quarter ended June 30, 2022, an increase of $6.8 million. The increase was attributable to professional services fees and expenses related to our proxy contest in connection with our 2023 annual general meeting of shareholders, and additional costs to support the growth of our business.
Net Loss. Net loss for the quarter ended June 30, 2023 was $29.1 million, compared to $17.0 million for the same period in 2022.
Conference Call and Webcast Reminder
MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s first quarter 2023 financial results. Individuals may participate in the live call via telephone by dialing (877) 407-3982 (domestic) or (201) 493-6780 (international). The webcast can be accessed live here on the Financials page in the Investors section of the MindMed website, https://mindmed.co/. The webcast will be archived on the Company’s website for at least 30 days after the conference call.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding anticipated upcoming milestones, and progress of enrollment of trials and studies; results and timing of and reporting of topline data from clinical trials; the potential benefits of the Company’s license with Catalent; the potential benefits of the Company’s product candidates, and the Company’s cash runway funding its operations into the first half of 2025. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 under headings such as “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Mind Medicine (MindMed) Inc.
ir@mindmed.co
media@mindmed.co
Mind Medicine (MindMed) Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited; in thousands, except share and per share amounts)
|
|
Three Months |
|
|
Six Months |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
14,777 |
|
|
$ |
9,326 |
|
|
$ |
27,375 |
|
|
$ |
19,567 |
|
General and administrative |
|
|
14,407 |
|
|
|
7,617 |
|
|
|
22,670 |
|
|
|
15,881 |
|
Total operating expenses |
|
|
29,184 |
|
|
|
16,943 |
|
|
|
50,045 |
|
|
|
35,448 |
|
Loss from operations |
|
|
(29,184 |
) |
|
|
(16,943 |
) |
|
|
(50,045 |
) |
|
|
(35,448 |
) |
Other income/(expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income, net |
|
|
1,311 |
|
|
|
82 |
|
|
|
2,595 |
|
|
|
83 |
|
Foreign exchange gain/(loss), net |
|
|
247 |
|
|
|
(89 |
) |
|
|
195 |
|
|
|
(44 |
) |
Change in fair value of 2022 USD Financing Warrants |
|
|
(1,504 |
) |
|
|
— |
|
|
|
(6,690 |
) |
|
|
— |
|
Other income/(expense) |
|
|
— |
|
|
|
(7 |
) |
|
|
— |
|
|
|
1 |
|
Total other income/(expense), net |
|
|
54 |
|
|
|
(14 |
) |
|
|
(3,900 |
) |
|
|
40 |
|
Net loss |
|
|
(29,130 |
) |
|
|
(16,957 |
) |
|
|
(53,945 |
) |
|
|
(35,408 |
) |
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss on foreign currency translation |
|
|
(279 |
) |
|
|
(147 |
) |
|
|
(265 |
) |
|
|
(196 |
) |
Comprehensive loss |
|
$ |
(29,409 |
) |
|
$ |
(17,104 |
) |
|
$ |
(54,210 |
) |
|
$ |
(35,604 |
) |
Net loss per common share, basic and diluted |
|
$ |
(0.76 |
) |
|
$ |
(0.60 |
) |
|
$ |
(1.41 |
) |
|
$ |
(1.26 |
) |
Weighted-average common shares, basic and diluted |
|
|
38,576,394 |
|
|
|
28,242,026 |
|
|
|
38,329,919 |
|
|
|
28,196,789 |
|
Mind Medicine (MindMed) Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
116,895 |
|
|
$ |
142,142 |
|
Prepaid and other current assets |
|
|
2,896 |
|
|
|
3,913 |
|
Total current assets |
|
|
119,791 |
|
|
|
146,055 |
|
Goodwill |
|
|
19,918 |
|
|
|
19,918 |
|
Intangible assets, net |
|
|
2,108 |
|
|
|
3,689 |
|
Other non-current assets |
|
|
268 |
|
|
|
331 |
|
Total assets |
|
$ |
142,085 |
|
|
$ |
169,993 |
|
|
|
|
|
|
|
|
||
Liabilities and Shareholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
8,577 |
|
|
$ |
2,111 |
|
Accrued expenses |
|
|
9,950 |
|
|
|
5,877 |
|
2022 USD Financing Warrants |
|
|
16,594 |
|
|
|
9,904 |
|
Total current liabilities |
|
|
35,121 |
|
|
|
17,892 |
|
Other liabilities, long-term |
|
|
992 |
|
|
|
1,184 |
|
Total liabilities |
|
|
36,113 |
|
|
|
19,076 |
|
|
|
|
|
|
|
|
||
Shareholders' Equity: |
|
|
|
|
|
|
||
Common shares, no par value, unlimited authorized as of |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
354,023 |
|
|
|
344,758 |
|
Accumulated other comprehensive income |
|
|
362 |
|
|
|
627 |
|
Accumulated deficit |
|
|
(248,413 |
) |
|
|
(194,468 |
) |
Total shareholders' equity |
|
|
105,972 |
|
|
|
150,917 |
|
Total liabilities and shareholders' equity |
|
$ |
142,085 |
|
|
$ |
169,993 |
|